EcoDrugPlus

Fyn Proto-Oncogene, Src Family Tyrosine Kinase

Ensembl ID : ENSBTAG00000011851
Gene Symbol: FYN
57 Enzyme and pathways 5 Cross references
276 Possible Orthologues:

G Protein-Coupled Receptor 119

Ensembl ID : ENSBTAG00000014770
Gene Symbol: GPR119
5 Enzyme and pathways 5 Cross references
187 Possible Orthologues:

Hck Proto-Oncogene, Src Family Tyrosine Kinase

Ensembl ID : ENSBTAG00000007932
Gene Symbol: HCK
7 Enzyme and pathways 5 Cross references
218 Possible Orthologues:

Il2 Inducible T Cell Kinase

Ensembl ID : ENSBTAG00000000306
Gene Symbol: ITK
7 Enzyme and pathways 5 Cross references
219 Possible Orthologues:

Janus Kinase 1

Ensembl ID : ENSBTAG00000003147
Gene Symbol: JAK1
38 Enzyme and pathways 5 Cross references
250 Possible Orthologues:

Janus Kinase 3

Ensembl ID : ENSBTAG00000020904
Gene Symbol: JAK3
19 Enzyme and pathways 5 Cross references
115 Possible Orthologues:

Kit Proto-Oncogene, Receptor Tyrosine Kinase

Ensembl ID : ENSBTAG00000002699
Gene Symbol: KIT
11 Enzyme and pathways 5 Cross references
222 Possible Orthologues:

Kras Proto-Oncogene, Gtpase

Ensembl ID : ENSBTAG00000009778
Gene Symbol: KRAS
81 Enzyme and pathways 5 Cross references
215 Possible Orthologues:

Lck Proto-Oncogene, Src Family Tyrosine Kinase

Ensembl ID : ENSBTAG00000012695
Gene Symbol: LCK
39 Enzyme and pathways 5 Cross references
132 Possible Orthologues:

Lyn Proto-Oncogene, Src Family Tyrosine Kinase

Ensembl ID : ENSBTAG00000020034
Gene Symbol: LYN
46 Enzyme and pathways 5 Cross references
209 Possible Orthologues:

Malt1 Paracaspase

Ensembl ID : ENSBTAG00000027916
Gene Symbol: MALT1
13 Enzyme and pathways 5 Cross references
209 Possible Orthologues:

Mapk Activated Protein Kinase 2

Ensembl ID : ENSBTAG00000038107
Gene Symbol: MAPKAPK2
53 Enzyme and pathways 5 Cross references
251 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).